Six month delivery of GDNF from PLGA/vitamin E biodegradable microspheres after intravitreal injection in rabbits

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Pharmaceutical Sciences

• Publication date

  2017-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejps.2017.02.037PMID 28259830
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty of 1000 evaluation for GDNF, NGF and BDNF as therapeutic options for neurodegeneration.

  2016cited by this paper
• Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology.

  2015cited by this paper
• Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration.

  2015cited by this paper
• Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development.

  2015cited by this paper
• Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data.

  2015cited by this paper
• Current nanotechnological strategies for treating glaucoma.

  2014cited by this paper
• Müller cells and microglia of the mouse eye react throughout the entire retina in response to the procedure of an intravitreal injection.

  2014influential reference
• Safety evaluation of poly(lactic-co-glycolic acid)/poly(lactic-acid) microspheres through intravitreal injection in rabbits

  2014cited by this paper
• Determination of triamcinolone acetonide in silicone oil and aqueous humor of vitrectomized rabbits' eyes: Application for a pharmacokinetic study with intravitreal triamcinolone acetonide injections (Kenalog® 40).

  2014cited by this paper
• The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies.

  2014cited by this paper
• Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases.

  2014cited by this paper
• Mitochondria-derived reactive oxygen species mediate caspase-dependent and -independent neuronal deaths.

  2014cited by this paper
• Photoreceptor cell death and rescue in retinal detachment and degenerations.

  2013cited by this paper
• GDNF, NGF and BDNF as therapeutic options for neurodegeneration.

  2013cited by this paper
• Recent advances in ocular drug delivery

  2013cited by this paper
• Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

  2013cited by this paper
• Alzheimer's disease and glaucoma: mechanistic similarities and differences.

  2013influential reference
• Preservation of biological activity of glial cell line-derived neurotrophic factor (GDNF) after microencapsulation and sterilization by gamma irradiation.

  2012cited by this paper
• Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy

  2012cited by this paper
• The molecular basis of retinal ganglion cell death in glaucoma.

  2012cited by this paper
• Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.

  2011cited by this paper
• Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure.

  2011influential reference
• Neuroprotection in glaucoma - Is there a future role?

  2010cited by this paper
• Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.

  2010cited by this paper
• Application of rabbits in biomedical research: A review

  2010cited by this paper
• Mechanisms of retinal ganglion cell injury and defense in glaucoma.

  2010cited by this paper
• Variability of serum oxidative stress biomarkers relative to biochemical data and clinical parameters of glaucoma patients

  2010cited by this paper
• A spheres-in-sphere structure for improving protein-loading poly (lactide-co-glycolide) microspheres

  2010cited by this paper
• Alpha-tocopherol: looking beyond an antioxidant

  2009cited by this paper
• Delayed administration of glial cell line-derived neurotrophic factor (GDNF) protects retinal ganglion cells in a pig model of acute retinal ischemia.

  2009cited by this paper
• Pharmacokinetics of intravitreal glial cell line-derived neurotrophic factor: experimental studies in pigs.

  2009cited by this paper
• COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) APPENDIX 1 TO THE GUIDELINE ON CLINICAL EVALUATION OF DIAGNOSTIC AGENTS (CPMP/EWP/1119/98 REV. 1) ON IMAGING AGENTS DRAFT AGREED BY EFFICACY WORKING PARTY April 2008 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION

  2009cited by this paper
• Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone.

  2009cited by this paper
• The potential value of natural antioxidative treatment in glaucoma.

  2008cited by this paper
• The rabbit as an animal model for post-natal vitreous matrix differentiation and degeneration

  2008cited by this paper
• Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres.

  2007cited by this paper
• Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma.

  2007influential reference
• Improvement of a bovine serum albumin microencapsulation process by screening design.

  2007cited by this paper
• Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse.

  2005cited by this paper
• Bioanalytical Method Validation for Macromolecules in Support of Pharmacokinetic Studies

  2005cited by this paper
• In vitro study of GDNF release from biodegradable PLGA microspheres.

  2004cited by this paper
• Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.

  2002cited by this paper
• Therapy of neurodegenerative diseases using neurotrophic factors: cell biological perspective

  2002cited by this paper
• Biodegradable microspheres for vitreoretinal drug delivery.

  2001cited by this paper
• Biodegradable microspheres for intraocular drug administration

  2001cited by this paper
• [Biodegradable microspheres for intraocular drug administration].

  2001cited by this paper
• Neurotrophic factors in Alzheimer's and Parkinson's disease brain.

  2000cited by this paper
• Human glial cell-line-derived neurotrophic factor: a structure-function analysis.

  2000cited by this paper
• Expression of receptors for glial cell line-derived neurotrophic factor (GDNF) and neurturin in the inner blood-retinal barrier of rats.

  2000cited by this paper
• In vivo neurotrophic effects of GDNF on axotomized retinal ganglion cells

  1997cited by this paper
• Antiproliferative effect of intravitreal alpha-tocopherol and alpha-tocopheryl-acid-succinate in a rabbit model of PVR.

  1997cited by this paper
• Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus.

  1997cited by this paper
• Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres.

  1995cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper
• Intraocular pressure and glaucoma.

  1989cited by this paper

• Advancing glaucoma treatment with nanotechnology: a new frontier in ophthalmology.

  2025cites this paper
• Eye Drops to smart gels: The future of ocular drug delivery

  2025cites this paper
• Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma

  2025cites this paper
• Emerging trends in long-acting sustained drug delivery for glaucoma management

  2025cites this paper
• Is There an Implication of Nutrition and Lifestyle Habits in Glaucoma Disease? A Systematic Review

  2024cites this paper
• Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

  2024cites this paper
• Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma

  2023cites this paper
• Future directions of glaucoma treatment: emerging gene, neuroprotection, nanomedicine, stem cell, and vascular therapies

  2023cites this paper
• Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

  2023cites this paper
• Long-acting drug delivery systems for ocular therapies

  2022cites this paper
• Regenerative nanomedicine applications for neurodegenerative diseases of central nervous system

  2021cites this paper
• A Safe GDNF and GDNF/BDNF Controlled Delivery System Improves Migration in Human Retinal Pigment Epithelial Cells and Survival in Retinal Ganglion Cells: Potential Usefulness in Degenerative Retinal Pathologies

  2021cites this paper
• Co-delivery of glial cell–derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases

  2021cites this paper
• Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration.

  2021cites this paper
• The progress and application of vitamin E encapsulation – A review

  2021cites this paper
• Reported evidence of vitamin E protection against cataract and glaucoma.

  2021cites this paper
• Microparticle Products for the Eye: Preformulation, Formulation, and Manufacturing Considerations

  2021cites this paper
• Neurotrophic Factors in Glaucoma and Innovative Delivery Systems

  2020cites this paper
• Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment

  2020cites this paper
• Retinal Cell Protection in Ocular Excitotoxicity Diseases. Possible Alternatives Offered by Microparticulate Drug Delivery Systems and Future Prospects

  2020cites this paper
• Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier

  2019cites this paper
• Primary tissue for cellular brain repair in Parkinson's disease: Promise, problems and the potential of biomaterials

  2019cites this paper
• Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases.

  2019cites this paper
• 3D cell‐laden polymers to release bioactive products in the eye

  2019cites this paper
• Therapeutic vitamin delivery: Chemical and physical methods with future directions

  2019cites this paper
• Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review

  2019cites this paper
• Effect of inner pH on peptide acylation within PLGA microspheres.

  2019cites this paper
• Trojan Microparticles Potential for Ophthalmic Drug Delivery.

  2019cites this paper
• Comparative analysis of retinal ganglion cell damage in three glaucomatous rat models

  2018cites this paper
• Effect of size on the in vitro / in vivo drug release and degradation of exenatide-loaded PLGA microspheres

  2018cites this paper
• Regenerative medicine in the retina: from stem cells to cell replacement therapy

  2018cites this paper
• Title : 3 D cell-laden polymers to release bioactive products in the eye

  2018cites this paper
• Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice

  2018cites this paper
• Novel technologies for the delivery of ocular therapeutics in glaucoma

  2017cites this paper
• Sustained release of intravitreal flurbiprofen from a novel drug‐in‐liposome‐in‐hydrogel formulation☆

  2017cites this paper
• Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress

  2017cites this paper